The Dow Chemical Company

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Ruth A Richard

Peter S Mezes

Kimberly S Johnson

Jeffrey Schlom

Eduardo Agustin Padlan

Joseph A Affholter

Syed V S Kashmiri

Nicolas J Kotite

Liming Shu

Novel composite and humanized anti-TAG-72 monoclonal antibodies, antibody fragments, and derivatives thereof using human subgroup IV kappa light chain framework regions.

Composite antibodies of humanized human subgroup IV light chain capable of binding to TAG-72

Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains

The present invention discloses novel proteins which are dimers and multimers of single chain polypeptides. The single chain polypeptides having two domains derived from the immunoglobulin superfamily which are joined by a peptide linker. The dimers and multimers being formed by non-covalent linking of the single chain polypeptides.

Dimer and multimer forms of single chain polypeptides

This invention concerns a subset of composite Hum4 V.sub.L, V.sub.H antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have variable regions with (1) V.sub.L segments derived from the human subgroup IV germline gene, and (2) a V.sub.H segment which is capable of combining with the V.sub.L to form a three dimensional structure having the ability to bind TAG-72. In vivo methods of treatment and diagnostic assay using these composite antibodies is also disclosed.

Composite antibodies of human subgroup IV light chain capable of binding

Growing community of inventors

Midland, MI, United States of America

Ruth A Richard